Denmark vs Oman: HIV/AIDS deaths averted by antiretroviral therapy
Denmark
129.29 deaths
in 2024
Oman
107.42 deaths
in 2024
Denmark rank
121st
Oman rank
124th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Denmark
- Oman
How they compare
Denmark currently reports 129.29 deaths against 107.42 deaths in Oman, a difference of 21.87 deaths.
That makes Denmark's figure about 1.2 times Oman's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Oman ahead.
Denmark ranks 121st and Oman ranks 124th of 157 countries.
Denmark has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Denmark | Oman | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 64.92 deaths | 0 deaths | 64.92 deaths | Denmark |
| 2000s | 230.44 deaths | 32.99 deaths | 197.45 deaths | Denmark |
| 2010s | 196.83 deaths | 53.22 deaths | 143.61 deaths | Denmark |
| 2020s | 141.56 deaths | 86.92 deaths | 54.64 deaths | Denmark |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Denmark or Oman?
- Denmark, at 129.29 deaths against 107.42 deaths in Oman as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Denmark and Oman?
- 21.87 deaths, with Denmark ahead.
- How many years of comparable data are there for Denmark and Oman?
- 35 years are reported by both, from 1990 to 2024.
- How do Denmark and Oman rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Denmark ranks 121st and Oman ranks 124th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.